MX2020005442A - FORMULACIÓN FARMACÉUTICA DE 3A-ETINIL-3ß-HIDROXIANDROSTAN-17-ONA OXIMA. - Google Patents

FORMULACIÓN FARMACÉUTICA DE 3A-ETINIL-3ß-HIDROXIANDROSTAN-17-ONA OXIMA.

Info

Publication number
MX2020005442A
MX2020005442A MX2020005442A MX2020005442A MX2020005442A MX 2020005442 A MX2020005442 A MX 2020005442A MX 2020005442 A MX2020005442 A MX 2020005442A MX 2020005442 A MX2020005442 A MX 2020005442A MX 2020005442 A MX2020005442 A MX 2020005442A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulation
hydroxyandrostan
ethynyl
oxime
optionally
Prior art date
Application number
MX2020005442A
Other languages
English (en)
Inventor
Magnus Doverskog
Paul Alhadeff
Maja Johansson
Thomas Meijer
Nicolaas Schipper
Original Assignee
Umecrine Cognition Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine Cognition Ab filed Critical Umecrine Cognition Ab
Publication of MX2020005442A publication Critical patent/MX2020005442A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención está dirigida a una formulación farmacéutica novedosa que comprende 3a-etinil-3ß-hidroxiandrostan- 17-ona oxima en una cantidad de 0.1-10% en peso del peso total de la composición; y un vehículo que comprende (a) 45-100% de un monoéster; (b) opcionalmente hasta 51% de un diéster; y (c) opcionalmente hasta aproximadamente 10% de un triéster. También se reclama un método para el tratamiento de condiciones médicas como hipersomnia y encefalopatía hepática mediante el uso de una formulación farmacéutica como se reclama.
MX2020005442A 2017-11-27 2018-11-27 FORMULACIÓN FARMACÉUTICA DE 3A-ETINIL-3ß-HIDROXIANDROSTAN-17-ONA OXIMA. MX2020005442A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762590757P 2017-11-27 2017-11-27
PCT/EP2018/082727 WO2019102040A1 (en) 2017-11-27 2018-11-27 PHARMACEUTICAL FORMULATION OF 3α-ETHYNYL-3β-HYDROXYANDROSTAN-17-ONE OXIME

Publications (1)

Publication Number Publication Date
MX2020005442A true MX2020005442A (es) 2022-03-30

Family

ID=64556898

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005442A MX2020005442A (es) 2017-11-27 2018-11-27 FORMULACIÓN FARMACÉUTICA DE 3A-ETINIL-3ß-HIDROXIANDROSTAN-17-ONA OXIMA.

Country Status (11)

Country Link
US (2) US10603326B2 (es)
EP (1) EP3716954A1 (es)
JP (1) JP7314459B2 (es)
KR (1) KR20200093008A (es)
CN (1) CN111432805B (es)
AU (1) AU2018374029B2 (es)
BR (1) BR112020010519A2 (es)
CA (1) CA3083555A1 (es)
IL (1) IL274893B1 (es)
MX (1) MX2020005442A (es)
WO (1) WO2019102040A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3716954A1 (en) 2017-11-27 2020-10-07 Umecrine Cognition AB Pharmaceutical formulation of 3 -ethynyl-3 -hydroxyandrostan-17-one oxime
EP4079307A1 (en) 2021-04-20 2022-10-26 Umecrine Cognition AB New medical use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE511313C2 (sv) 1997-01-13 1999-09-06 Gs Dev Ab Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol
GB9907715D0 (en) 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
US20040191207A1 (en) 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
JP2010502703A (ja) 2006-09-06 2010-01-28 メルク エンド カムパニー インコーポレーテッド 置換アミドの経口投与のための液体及び半固体の医薬製剤
EP2097437B1 (en) 2006-11-21 2015-05-27 Umecrine Cognition AB The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders
AU2011205821B2 (en) 2010-01-14 2013-07-25 Umecrine Mood Ab A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US9801819B2 (en) 2012-06-28 2017-10-31 Johnson & Johnson Consumer Inc. Racecadotril compositions
AR096459A1 (es) * 2013-06-03 2015-12-30 Tolmar Inc Composiciones de corticosteroides y método de fabricación
CA2935015C (en) * 2014-01-29 2022-05-31 Umecrine Cognition Ab Steroid compound for use in the treatment of hepatic encephalopathy
CA2950670A1 (en) 2014-06-17 2015-12-23 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate
WO2016033556A1 (en) * 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
KR101679992B1 (ko) 2015-12-31 2016-11-28 주식회사 유유제약 프로필렌글리콜 모노라우레이트를 포함하는 두타스테리드의 약학적 조성물 및 이의 제조 방법
KR101716878B1 (ko) 2016-05-12 2017-03-15 주식회사 유유제약 글리세롤 지방산에스테르유도체 또는 프로필렌글리콜 지방산에스테르유도체를 함유한 두타스테리드와 타다라필의 복합 캡슐제제 조성물 및 이의 제조방법
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
EP3716954A1 (en) 2017-11-27 2020-10-07 Umecrine Cognition AB Pharmaceutical formulation of 3 -ethynyl-3 -hydroxyandrostan-17-one oxime

Also Published As

Publication number Publication date
RU2020121142A (ru) 2021-12-29
EP3716954A1 (en) 2020-10-07
CA3083555A1 (en) 2019-05-31
CN111432805A (zh) 2020-07-17
WO2019102040A1 (en) 2019-05-31
US20200297737A1 (en) 2020-09-24
JP7314459B2 (ja) 2023-07-26
KR20200093008A (ko) 2020-08-04
AU2018374029B2 (en) 2024-01-11
US10603326B2 (en) 2020-03-31
US11123351B2 (en) 2021-09-21
IL274893A (en) 2020-07-30
BR112020010519A2 (pt) 2020-10-20
US20190358244A1 (en) 2019-11-28
RU2020121142A3 (es) 2022-03-28
IL274893B1 (en) 2024-04-01
JP2021504468A (ja) 2021-02-15
CN111432805B (zh) 2023-02-17
AU2018374029A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
PH12020550857A1 (en) Polycyclic compounds as allosteric shp2 inhibitors
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
PH12017501921A1 (en) Novel compounds
NZ708593A (en) Novel pyrazole derivative
MX2016010373A (es) Rapamicina para el tratamiento de linfangioleiomiomatosis.
WO2015104292A3 (en) Compounds for use in treating or preventing cancerous diseases
MX2016004530A (es) Rapamicina para el tratamiento de linfangioleiomiomatosis.
BR112016007329A2 (pt) composto, composição farmacêutica, e, método para tratamente de uma condição ou doença mediada por hsf1
MX2019007571A (es) Polimorfos.
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
MX352386B (es) Nuevos derivados quinona de cannabidiol.
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
BR112017008103A2 (pt) composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo.
BR112012017476B8 (pt) composto, composição, método para preparar uma composição, uso de um composto, e, métodos para inibir um alérgeno de peptidase do ácaro da poeira, para exterminar ácaros, e para controlar uma população de ácaros
MX367404B (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
MX2020005442A (es) FORMULACIÓN FARMACÉUTICA DE 3A-ETINIL-3ß-HIDROXIANDROSTAN-17-ONA OXIMA.
MX2019004580A (es) Formulaciones farmaceuticas y metodos para prepararlas.
BR112019008239A2 (pt) formulações aquosas, estáveis, injetáveis de capsaicina e uso médicos dos mesmos
MY183540A (en) Injectable buprenorphine formulation
BR112017016378A2 (pt) composições da pró-droga de fumarato de monometila
PH12020550947A1 (en) Polymorphs
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
EP3643302C0 (en) COMPOSITION WITH SESQUITERPENDERIVATE AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF MUSCLE DISEASES